SEATTLE, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 17th Annual Global Investment Conference on Wednesday, Sept. 9, 2015 at 9:10 a.m. Eastern Time in New York.
A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.
Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. Our current clinical-stage product candidates include ONT-380, an orally active and selective small molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting MUC1. We are developing preclinical product candidates in oncology and immune-oncology using our protocell technology. For more information, visit www.oncothyreon.com.
CONTACT: Investor and Media Relations Contact: Julie Rathbun Rathbun Communications 206-769-9219 firstname.lastname@example.org